HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joensuu, H. Articles by Ahonen, A. Search for Related Content PubMed PubMed Citation Articles by Joensuu, H. Articles by Ahonen, A.

Imaging of Metastases of Thyroid Carcinoma with Fluorine-18 Fluorodeoxyglucose

Departments of Radiotherapy and Radiology, Division of Nuclear Medicine, University Central Hospital of Turku, and Turku Medical Cyclotron Project, Turku, Finland

Correspondence: For reprints contact: Heikki Joensuu MD, Department of Radiotherapy, University Central Hospital of Turku, SF-20520 Turku, Finland.

ABSTRACT

Three patients with multiple metastases of thyroid carcinoma were studied with ¹⁸F-2-fluoro-2-deoxy-D-glucose (FDG) and iodine-131 (¹³¹I) imaging. Metastases that accumulated only FDG, only ¹³¹I, or both FDG and ¹³¹I could be demonstrated. Metabolic heterogeneity was seen between different metastases in all patients. The accumulation of FDG may also differ between different metastases of the same patient. The uptake of FDG in metastases was shown to increase parallel with their progression. Metastases of thyroid carcinoma that have ceased to accumulate ¹³¹I after treatment with radioiodine may still be demonstrated with FDG. Metastases that accumulate FDG, but not ¹³¹I, may behave more aggressively than metastases that accumulate ¹³¹I, but not FDG.

This article has been cited by other articles:

				A. Shammas, B. Degirmenci, J. M. Mountz, B. M. McCook, B. Branstetter, B. B. Bencherif, J. M. Joyce, S. E. Carty, H. A. Kuffner, and N. Avril 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer J. Nucl. Med., February 1, 2007; 48(2): 221 - 226. [Abstract] [Full Text] [PDF]

				N Khan, N Oriuchi, T Higuchi, H Zhang, and K Endo PET in the follow-up of differentiated thyroid cancer Br. J. Radiol., October 1, 2003; 76(910): 690 - 695. [Abstract] [Full Text] [PDF]

				S. Szakall Jr., O. Esik, G. Bajzik, I. Repa, G. Dabasi, I. Sinkovics, P. Agoston, and L. Tron 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma J. Nucl. Med., January 1, 2002; 43(1): 66 - 71. [Abstract] [Full Text] [PDF]

				T. Shiga, E. Tsukamoto, K. Nakada, K. Morita, T. Kato, M. Mabuchi, K. Yoshinaga, C. Katoh, Y. Kuge, and N. Tamaki Comparison of 18F-FDG, 131I-Na, and 201Tl in Diagnosis of Recurrent or Metastatic Thyroid Carcinoma J. Nucl. Med., March 1, 2001; 42(3): 414 - 419. [Abstract] [Full Text]

				B. Schluter, K. H. Bohuslavizki, W. Beyer, M. Plotkin, R. Buchert, and M. Clausen Impact of FDG PET on Patients with Differentiated Thyroid Cancer Who Present with Elevated Thyroglobulin and Negative 131I Scan J. Nucl. Med., January 1, 2001; 42(1): 71 - 76. [Abstract] [Full Text] [PDF]

				W. Wang, H. Macapinlac, S. M. Larson, S. D. J. Yeh, T. Akhurst, R. D. Finn, J. Rosai, and R. J. Robbins [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2291 - 2302. [Abstract] [Full Text]